{
    "relation": [
        [
            "",
            "Exenatide Once Weekly",
            "Insulin Detemir"
        ],
        [
            "Description",
            "Exenatide once weekly : subcutaneous injection, 2mg, once a week",
            "Insulin detemir : subcutaneous injection, with dosage titrated according to the detemir label and published titration schedule, once or twice a day"
        ]
    ],
    "pageTitle": "Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01003184?sect=X4015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989790.89/warc/CC-MAIN-20150728002309-00255-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 878897116,
    "recordOffset": 878881498,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 6 patients who were enrolled and randomized, subsequently discontinued the study before receiving study drug. These patients were not included in analysis. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: exenatide once weekly Drug: insulin detemir Interventions: Type 2 Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Exenatide Once Weekly \u00a0 \u00a0 Insulin Detemir \u00a0 STARTED \u00a0 \u00a0 111 \u00a0 \u00a0 111 \u00a0 Full Analysis Set (FAS) \u00a0 \u00a0 111 \u00a0 \u00a0 105 \u00a0 COMPLETED \u00a0 \u00a0 92 \u00a0 \u00a0 99 \u00a0 NOT COMPLETED \u00a0 \u00a0 19 \u00a0 \u00a0 12 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}